#USA #Los Angeles #PTSD Treatment #Ketamine #Oxytocin

A Breakthrough in Mental Health Treatment

Mental health challenges such as treatment-resistant depression and PTSD continue to affect millions across the globe, leaving many feeling hopeless. Fortunately, Dr. David Mahjoubi, a board-certified anesthesiologist and the founder of NutraBrain Clinic in Los Angeles, has developed a pioneering solution to address these challenging conditions—a compounded nasal spray that combines ketamine and oxytocin.

Understanding the Problem

For over a decade, Dr. Mahjoubi has treated patients struggling with depression and PTSD, many of whom did not find relief with conventional antidepressants. A recurring theme for these patients was feeling emotionally disconnected even when their depression symptoms improved. This disconnection not only affects their quality of life but also strains their relationships with loved ones.

The Innovative Solution

After years of clinical experience, Dr. Mahjoubi introduced a novel ketamine-oxytocin nasal spray, available via telehealth in 13 states under physician supervision. The formulation uniquely merges low-dose ketamine—a substance known for its rapid antidepressant effects—with oxytocin, often referred to as the 'bonding hormone'.

Mechanism of Action

Ketamine has garnered attention for its ability to interact with NMDA receptors, enhancing neuroplasticity and offering quicker relief for treatment-resistant depression compared to traditional SSRIs. On the other hand, oxytocin plays a crucial role in fostering social bonds and emotional connections. By combining these two powerful agents, the nasal spray aims to tackle both mood and relational connection, addressing aspects of mental health that previous treatments often overlook.

Target Patient Profile

This formulation is particularly beneficial for individuals suffering from PTSD, especially those who experience emotional numbness and attachment challenges—conditions that are frequently at the core of PTSD and are often overlooked in conventional treatment approaches. Furthermore, it addresses the emotional blunting reported by some long-term SSRI users, presenting an innovative alternative that considers the emotional dimensions of mental health treatment.

Telehealth Accessibility

The NutraBrain Clinic facilitates access to this groundbreaking treatment through a monthly membership of $69, which includes ongoing clinical support and direct email access to Dr. Mahjoubi. As telehealth continues to reshape the healthcare landscape, this model not only broadens access but also allows for personalized treatment adjustments, ensuring each patient receives tailored care.

Clinical Philosophy

Dr. Mahjoubi emphasizes that the integration of ketamine and oxytocin is not merely a marketing gimmick but rather a strategic clinical approach designed to bridge the gap between mood restoration and emotional connectivity. According to Dr. Mahjoubi, “The most common complaint I heard during my decade running brick-and-mortar ketamine clinics wasn't that the treatment didn't work; it was that even when their depression lifted, patients still felt emotionally walled off from the people they loved.”

Conclusion

In summary, Dr. David Mahjoubi's compounded nasal spray represents a significant advancement in the fight against treatment-resistant depression and PTSD. By addressing both emotional and relational challenges, this innovative treatment holds the promise of fostering healing and reconnection for individuals who have long felt isolated in their struggles. As mental health continues to gain recognition as a crucial aspect of overall well-being, the work being done at NutraBrain Clinic embodies the hope that compassionate and effective solutions can make a difference in the lives of many.

For more information, visit NutraBrain Clinic's website.